GLPBio

MIF-1 TFA

Catalog No.: GC61955Purity:>98.00%Synonyms: Pro-Leu-Gly-NH2 TFA; Melanostatin TFA
COASDSData Sheet
MIF-1 TFA is an antibiotic with melanin synthesis inhibitory activity that strongly inhibits melanin formation.

Products are for research use only. Not for human use. We do not sell to patients.

MIF-1 TFA
Cas No.: 35240-69-8
1mgIn Stock
$10.00
1
5mgIn Stock
$21.00
1
10mgIn Stock
$30.00
1
25 mgIn Stock
$48.00
1
50 mgIn Stock
$80.00
1
100 mgIn Stock
$124.00
1
Tel: (909) 407-4943 / (909) 689-7124Email: sales@glpbio.com

Citations

No citations are currently available for this product. Below are selected publications citing GlpBio products.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

Description

MIF-1 TFA is an antibiotic with melanin synthesis inhibitory activity that strongly inhibits melanin formation[1]. MIF-1 TFA activates the dopamine D2 receptor, regulating dopamine neurotransmission within the central nervous system and enhancing the behavioral effects of levodopa[2]. MIF-1 TFA has been widely used to promote the development of dopamine D2 receptors in the rat striatum[3].

In vitro, MIF-1 TFA treatment (10ng/ml) for 1 hour increased the expression of c-Fos in SH-SY5Y cells and regulated the pERK and pSTAT3 pathways[4].

In vivo, a single intravenous injection of MIF-1 TFA (10µg) resulted in an increase in the expression of c-Fos in the mouse brain 4 hours later[4].

References:

[1] Ishihara Y, Oka M, Tsunakawa M, et al. Melanostatin, a new melanin synthesis inhibitor production, isolation, chemical properties, structure and biological activity[J]. The Journal of Antibiotics, 1991, 44(1): 25-32.

[2] Bhagwanth S, Mishra R K, Johnson R L. Development of peptidomimetic ligands of Pro-Leu-Gly-NH2 as allosteric modulators of the dopamine D2 receptor[J]. Beilstein journal of organic chemistry, 2013, 9(1): 204-214.

[3] Saleh M I, Kostrzewa R M. MIF-1 attenuates spiroperidol alteration of striatal dopamine D2 receptor ontogeny[J]. Peptides, 1989, 10(1): 35-39.

[4] Khan R S, Yu C, Kastin A J, et al. Brain Activation by Peptide Pro‐Leu‐Gly‐NH2 (MIF‐1)[J]. International journal of peptides, 2010, 2010(1): 537639.

Protocol

Cell experiment [1]:

Cell lines

 SH-SY5Y cells

Preparation Method

 SH-SY5Y cells were cultured in DMEM medium supplemented with 10% fetal bovine serum, at 37°C in an incubator with 5% CO2. Sixteen hours after serum starvation, the cells were treated with MIF-1 TFA (10ng/ml for different time intervals (0, 1, 2, and 3h). c-Fos expression was measured.

Reaction Conditions

 10ng/ml; 0, 1, 2, and 3h

Applications

 MIF-1 TFA enhanced the c-Fos expression in SH-SY5Y cells in a time-dependent manner.
Animal experiment [2]:

Animal models

 Sprague-Dawley albino rats

Preparation Method

Pregnant Sprague-Dawley albino rats were kept at constant environmental and nutritional conditions at room temperature with a 12h/12h light/dark cycle and allowed free access to standard laboratory food and water throughout the experiment. Rat pups were treated i.p. once each day from birth for 32 days, with the diluent, consisting of saline (0.9%) plus saline containing tartaric acid (0.5%) and acetic acid (0.5mM); or spiroperidol (1mg/kg); or MIF-1 TFA (1mg/kg); or spiroperidol plus MIF-1 TFA. Rat pups were weaned at 4 weeks and killed at 8 weeks by decapitation. Striata were dissected from each brain for analysis.

Dosage form

1mg/kg/day; 32 days; i.p.

Applications

MIF-1 TFA attenuated spiroperidol-induced impairment of development of striatal dopamine D2 receptors in rats.

References:

[1] Khan R S, Yu C, Kastin A J, et al. Brain Activation by Peptide Pro‐Leu‐Gly‐NH2 (MIF‐1)[J]. International journal of peptides, 2010, 2010(1): 537639.

[2] Bhagwanth S, Mishra R K, Johnson R L. Development of peptidomimetic ligands of Pro-Leu-Gly-NH2 as allosteric modulators of the dopamine D2 receptor[J]. Beilstein journal of organic chemistry, 2013, 9(1): 204-214.

Product Documents

Purity:>98.00%Appearance:A solid
COASDSData Sheet

Chemical Properties

CAS No.
35240-69-8
Synonyms
Pro-Leu-Gly-NH2 TFA; Melanostatin TFA
Molecular Formula
C15H25F3N4O5
Molecular Weight
398.38
Solubility
DMSO : 125 mg/mL (313.77 mM)
Storage
-20°C, protect from light
General tips
Select a suitable solvent according to the product solubility data. Once prepared, aliquot the stock solution to avoid repeated freeze-thaw cycles.
Use stock solutions within 6 months when stored at -80°C or within 1 month when stored at -20°C.
To improve solubility, warm the tube to 37°C and sonicate it for an appropriate period.
Shipping Condition
Evaluation samples are shipped with blue ice. Other available sizes are shipped at room temperature or with blue ice upon request.

CalculatorsMolarity / Dilution / Molecular Weight / Unit Conversion / In Vivo Formulation / Solubility

g/mol

Reviews

Review for MIF-1 TFA

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%